Skandinaviska Enskilda Banken AB publ Acquires 160,128 Shares of KalVista Pharmaceuticals, Inc. $KALV

Skandinaviska Enskilda Banken AB publ lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 391.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 200,991 shares of the specialty pharmaceutical company’s stock after purchasing an additional 160,128 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in KalVista Pharmaceuticals were worth $2,449,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in KALV. AQR Capital Management LLC bought a new stake in KalVista Pharmaceuticals during the 1st quarter valued at about $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after acquiring an additional 2,939 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of KalVista Pharmaceuticals by 3.7% during the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock valued at $3,923,000 after acquiring an additional 12,263 shares in the last quarter. Whalen Wealth Management Inc. purchased a new stake in shares of KalVista Pharmaceuticals in the second quarter valued at approximately $124,000. Finally, Emerald Advisers LLC grew its stake in KalVista Pharmaceuticals by 15.6% in the second quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock worth $11,735,000 after purchasing an additional 139,859 shares in the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In related news, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the transaction, the chief financial officer owned 10,529 shares in the company, valued at $141,615.05. The trade was a 29.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $71,231.20. Following the sale, the insider directly owned 131,831 shares of the company’s stock, valued at $1,773,126.95. The trade was a 3.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 33,556 shares of company stock valued at $484,606 in the last 90 days. Insiders own 4.30% of the company’s stock.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $15.83 on Friday. The company has a market capitalization of $800.14 million, a PE ratio of -4.01 and a beta of -0.19. The company has a 50-day simple moving average of $15.50 and a two-hundred day simple moving average of $13.88. KalVista Pharmaceuticals, Inc. has a one year low of $9.23 and a one year high of $19.00. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their price target on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Finally, TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.